Diabetes and its complications remain major causes of morbidity and mortality in the U.S. (1). Estimated economic costs of diabetes in medical expenditures and lost productivity total $174 billion in the U.S. in 2007 (2). In 1999–2002, the crude prevalence of diabetes (diagnosed and undiagnosed) in the U.S. was 9.3%, of which 30% was undiagnosed based on fasting plasma glucose (FPG) (3). A further 26% had impaired
fasting glucose (IFG). IFG increases the risk of diabetes (4), and both undiagnosed
diabetes and IFG are associated with diabetes complications and risk factors
(4,5). These prevalence data came from the National Health and Nutrition
Examination Survey (NHANES), the only national survey that captures information
on diabetes and pre-diabetes from an interview and FPG